Targeted Oncology1d
No OS Difference Among First-Line CDK4/6 Inhibitors in HR+/HER2- mBC
Patients included in the trial had HR+/HER2– metastatic breast cancer, were 18 years or older, and started index treatment ...
Cure Today1d
Camizestrant Plus Kisqali May Be Safe, Effective in ER+/HER2- Breast Cancer
Among patients with ER-positive/HER2-negative advanced breast cancer, treatment with camizestrant in combination with Kisqali ...
Medindia2d
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that underscore the extended efficacy beyond the duration of treatment in ...
Cure Today2d
Looking Ahead After Kisqali’s FDA Approval for Adjuvant Treatment of Early Breast Cancer
Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...